The medical black technology system of the top student

Zheng Wen watched silently as the mother and daughter discussed. He did not have the right to decide whether to use clinical drugs.

After discussing for a while, Professor Wu’s daughter suddenly looked at Zheng Wen and asked, “Director Zheng, didn’t the foreign Pfizer company say it has a targeted drug for the treatment of pancreatic cancer?

Their drug has gone through clinical trials and is sufficiently guaranteed. Can you get this drug?

Zheng Wen sighed. If he had that medicine, would he still worry about this matter?

Zheng Wen said: You should also know that Pfizer has already issued a notice that this drug will not be considered for domestic marketing.

Mrs. Wu asked on the side: Is there no other way?

Zheng Wen shook his head. In this situation, there are only two options before him, one is conservative treatment, and the other is to participate in clinical trials.

Conservative treatment is definitely a dead end. With the current situation, he can only live for two to three months at most.

If you participate in a clinical trial, you still have a certain chance.

Professor Wu's daughter also gritted her teeth and said, Mom, if it doesn't work, let's transfer the hospital to a foreign country!

After hearing this, Zheng Wen's expression didn't change on the surface, but he couldn't help but frown in his heart.

However, the decision-making power rests with the other party, and he is not prepared to say anything. After all, this is someone else's family matter, and it is not easy for him as an outsider to interfere.

Ahem!

However, just as Mrs. Wu and her daughter were discussing, a coughing sound suddenly sounded in the ward.

Everyone looked back and found Professor Wu lying on the hospital bed who had woken up at some point.

Professor Wu said in a hoarse voice: Director Zheng, just use that medicine.

Obviously, Professor Wu had been awake for a long time, and he had heard the previous conversations, but he had not spoken.

Zheng Wen was stunned for a moment: Professor Wu, what do you mean?

I agree to participate in the clinical trial. Let's use the clinical drug. Professor Wu said.

Professor Wu's words shocked Mrs. Wu and her daughter. Professor Wu's daughter even looked puzzled: Why, Dad?

Professor Wu just waved his hand and said, It's too troublesome. I can't bear this kind of trouble.

But.

Professor Wu's daughter wanted to say something else, but was directly interrupted by Professor Wu: Okay, that's it, I've already decided.

Zheng Wen didn't say anything. He took out the application form that he had already prepared and asked Professor Wu to sign it.

Zheng Wen put the application away and said, Okay, Professor Wu, we will arrange it as soon as possible.

Stanford University.

Lu Shengping frowned and looked through some recent test data.

After a long time, Lu Shengping shook his head and gave up on this batch of failed test data.

After he turned off the software on the computer screen, he rubbed his brow feebly.

He is a Chinese professor at Stanford University School of Medicine, and his research mainly focuses on pancreatic cancer.

But recently his research has hit a bottleneck.

Over the years, he has been studying the mechanism of pancreatic cancer, trying to find a drug molecule that can act on pancreatic cancer.

Unfortunately, there has been little progress in his research recently.

This feeling is like being restricted by a thin film. As long as he breaks through this thin film, he will be greeted by another vast world. But the problem is that he has never been able to break through this thin film.

This made Lu Shengsheng feel very distressed.

Ding dong.

A prompt interrupted Lu Shengping's thoughts. Lu Shengping glanced at the computer. It was a prompt from the mailbox that there was a new email.

Lu Shengping opened the email and found that it was an email sent to him by the editor of Cell journal.

The meaning is quite simple. Cell received a paper about research on pancreatic cancer.

Among the current scholars studying pancreatic cancer, Lu Shengping is more authoritative, so I would like to ask Lu Shengping to be the reviewer of this paper.

Colleagues?

Lu Shengping raised his eyebrows, but it just so happened that he had no clue recently, so he wanted to see if he could get any ideas from the other party's article.

So Lu Shengping didn't think much about it, and immediately wrote back to Cell's editor and agreed to the matter.

Soon, the other party sent Lu Shengping another email with an attachment.

Lu Shengping didn't think much. He directly opened the attachment and glanced at the title of the paper.

However, with just one glance, Lu Shengping was immediately attracted by the title of this paper.

Targeting Pin1 can significantly inhibit CAF proliferation and achieve the effect of treating pancreatic cancer!

Is this a new target?

Lu Shengping suddenly became interested.

You should know that new targets have always been a hot spot in pancreatic cancer research, and many studies are conducted to find new targets.

However, the so-called new targets found in those studies can be said to have minimal effect on the treatment of pancreatic cancer.

I hope this paper can be of some value.

Lu Shengping was thinking as his eyes scanned the abstract of the paper.

Pin1 drives desmoplastic and immunosuppressive TME by acting on CAFs, while activating multiple cancer pathways

Thus, Pin1 inhibition simultaneously blocks multiple cancer pathways, disrupting the desmoplastic and immunosuppressive milieu, making pancreatic cancer curable.

Hmm. Just so-so.

After Lu Shengping glanced at the abstract of the paper, he silently made an evaluation in his heart.

At the same time, the expectations in my heart could not help but drop a level.

In his opinion, there was really nothing outstanding about this summary.

But as a reviewer, he naturally cannot completely reject a paper based on an abstract.

Lu Shengping then continued to look down.

The research method is also very general, just a controlled experiment, nothing too outstanding.

Lu Shengping watched while silently giving his own evaluation in his heart.

If I have to say there is something good about this paper.

Maybe it’s because the ideas are rigorous and the data is solid, and then there’s a good picture.

This is worthy of extra points.

However, this is not enough to pass the manuscript here.

Soon, Lu Shengping saw the results of the subsequent experiments.

Peptidyl prolyl isomerase Pin1 functionally, in addition to activating multiple cancer pathways, also induces cancer cells to endocytose and degrade PD-L1 and ENT1 by acting on stromal cells and by acting on pS929-HIP1R

Pin1 drives the desmoplastic and immunosuppressive TME and promotes tumor malignancy and drug resistance.

By inhibiting Pin1, pancreatic cancer lesions completely disappeared in 70% of mice.

Um!

completely! disappear?

Still 70%!

Lu Shengping, who was still lazy at first, suddenly sat up straight when he saw this line of words, and his whole face wanted to be pressed against the computer screen!

There is something in this paper!